Deerfield Management’s Jim Flynn on CRISPR, and that $550M new fund
CRISPR gene editing technology is one of the most intriguing growth fields in biotech, says Deerfield Management president Jim Flynn. The venture firm just launched a new $550 million fund, and it'll focus on seeding startups and funding new companies - and is very interested in this space.